Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered t cells take on Hard-to-Treat breast cancer

NCT ID NCT05989828

Recruiting now Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new cell therapy for people with advanced triple negative breast cancer that has stopped responding to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a specific marker called NY-ESO-1. The study aims to find the safest dose and check for side effects in about 20 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • USC / Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••